SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to widespread reports of users experiencing outages and technical issues, sparking frustration and concerns about the platform's reliability; some users are unable to access their accounts or execute trades. The issues are reportedly tied to a larger Amazon Web Services (AWS) outage, but the community is still expressing distrust and considering alternative platforms. Despite the technical difficulties, the stock price is up, leading to confusion and speculation about market manipulation.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GME is trending as some traders draw comparisons to BYND's recent surge, speculating whether GME could see a similar short squeeze; the community is actively discussing prior squeezes and potential catalysts. Some investors express frustration with GME's performance, while others remain optimistic about its long-term potential amid growing discussions around meme stocks and short squeeze opportunities.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending amid discussions about AI competition and its potential impact on Google's search dominance, with investors weighing the implications of new AI browser technologies. Community members are also focused on Google's AI investments and potential partnerships, particularly regarding its cloud infrastructure and Gemini AI model. Positive analyst ratings and potential earnings run-ups are contributing to the stock's current momentum.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to renewed community interest, possibly driven by its recent surpassing of a one-year high and BTIG adjusting their stance to a Buy rating with a target price of $40. Community members are actively discussing potential catalysts and upcoming opportunities related to the stock's momentum. The company's focus on novel therapies for immune-related diseases and recent financing updates may also contribute to the heightened attention.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending following strong earnings and procedure growth, particularly with the da Vinci 5 system. The community is weighing the impact of tariffs and margin pressures against the company's long-term growth potential and market dominance in robotic surgery. Bullish sentiment is fueled by raised guidance and analysts' price targets, while some caution against high valuation and potential market volatility.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's upcoming earnings and Elon Musk's compensation plan are driving much of the current discussion. Community members are actively debating potential earnings outcomes, forward guidance, and the impact of Musk's pay package on shareholder value and stock performance. Additionally, some traders point to technical indicators and unusual options activity as potential signals for the stock's direction.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending due to a mixed Q3 earnings report and cautious forward guidance, sparking concerns about the near-term outlook despite a strong analog chip performance. Community discussions center on whether this drop represents a buying opportunity or signals deeper industry headwinds, with some analysts questioning the capital expenditure plan. Investors are also monitoring tariff implications and potential shifts in market share amid evolving US-China trade dynamics.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to a recent $1 billion capital raise via a convertible note offering, sparking discussions about dilution and the company's financial strategy. While some investors express concerns about potential dilution, others view the raise as a bullish move to fund satellite constellation deployment and secure long-term growth. The community is actively analyzing the offering's terms and speculating on upcoming catalysts, including potential partnerships and launch milestones.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

Six Flags ($FUN) is trending after NFL star Travis Kelce reportedly teamed up with activist investor Jana Partners to push for company changes. The community speculates about potential marketing strategies involving Kelce's fiance, Taylor Swift, while some express skepticism about the company's long-term prospects despite the recent investment news.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

$NERV is trending due to a significant financing deal aimed at advancing its schizophrenia treatment through Phase 3 trials, sparking excitement among retail investors. Community discussions revolve around the potential FDA catalyst and the stock's potential for further gains. The stock's substantial pre-market surge and high trading volume reflect the market's reaction to the news and the renewed focus on the company's prospects in the biotech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is AMLX Stock a Solid Choice Right Now? 

Amylyx has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

The U.S. Food and Drug Administration (FDA) announced on Thursday that it is withdrawing its approval of the new drug application (NDA) for Amylyx Pharmaceuticals’ (AMLX) Relyvrio.Amylyx has voluntarily requested that the FDA withdraw approval of this application and has waived its opportunity for a hearing, the agency <a target="_blank" rel="noopener noreferrer nofollow" href="https://public-inspection.federalregister.gov/2025-16646.pdf">said</a>. The FDA approved the application for Relyvrio for the treatment of amyotrophic lateral sclerosis (ALS) in adults in September 2022. Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a progressive, fatal neurodegenerative disorder that causes muscle weakness and paralysis by destroying motor neurons, the cells that control voluntary muscle movement.&nbsp;However, last year, the company reported to the agency that a late-stage trial evaluating the drug in patients living with ALS did not meet its prespecified goals. It also notified the agency that it plans to discontinue marketing of Relyvrio as of Oct. 31, 2024.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AMLX">AMLX stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels. Shares of the company traded 1% lower at the time of writing.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_2_17_49_PM_png_ec4ad4caa5.webp" alt="AMLX's Sentiment Meter and Message Volume as of 2:18 p.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>AMLX's Sentiment Meter and Message Volume as of 2:18 p.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company <a href="https://stocktwits.com/news-articles/markets/equity/amylyx-discontinues-investigative-therapy-program-in-rare-neurological-disorder/chsUG7LRdkv">reiterated</a> earlier this week that it has a cash runway until the end of 2026 on the heels of discontinuing its AMX0035 program in adults living with progressive supranuclear palsy.The decision to discontinue the program was made after it failed to show differences compared to the placebo on primary or secondary outcomes at week 24 in a mid-stage trial. The company will not initiate the late-stage portion of the program, it then said.AMLX stock is up 148% this year and approximately 349% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/li-auto-announces-lower-q3-delivery-outlook-despite-new-vehicle-launches/chs60e1RdZ2">Li Auto Announces Lower Q3 Delivery Outlook Despite New Vehicle Launches: Retail Sees i8, i6 Selling Like ‘Hot Cakes’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target

Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a cash runway until the end of 2026.

Equity

Amylyx Pharmaceuticals Inc. (AMLX) on Wednesday said that it is discontinuing its AMX0035 program in adults living with progressive supranuclear palsy.AMX0035 is an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol. The decision to discontinue the program was made after it failed to show differences compared to the placebo on primary or secondary outcomes at week 24 in a mid-stage trial. The company will not initiate the late-stage portion of the program, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-discontinue-orion-program-amx0035">said</a>.Progressive Supranuclear Palsy (PSP) is a rare, progressive neurological disorder characterized by problems with balance, eye movements, speech, and swallowing, often leading to frequent and unpredictable falls. According to Amylyx, the disease affects about seven in 100,000 people worldwide.On Stocktwits, retail sentiment around the <a href="https://stocktwits.com/symbol/AMLX">AMLX stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels. Shares of the company are down by 2% in the pre-market session.“While we are disappointed in these results, we believe these data will inform the PSP trial literature as well as deepen scientific understanding of this devastating disease,” said Camille L Bedrosian, Chief Medical Officer at Amylyx.Co-CEOs of Amylyx, Joshua Cohen and Justin Klee, said that the company’s priority remains on the late-stage trial of Avexitide, with enrollment expected to be completed in 2025 and topline data anticipated in the first half of 2026.Avexitide is an investigational, glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism.The company is also continuing development of AMX0035 in Wolfram syndrome, a rare, inherited genetic disorder, they said. Amylyx continues to expect its cash runway to extend through the end of 2026.AMLX stock is up by 142% this year and has jumped 330% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-recalls-nearly-356000-vehicles-in-us/chsUG1SRdkx">Ford Issues Nearly 356,000 Vehicles Recall In U.S., But Retail Investors Spot Emerging Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder

The decision to discontinue the program was made after AMX0035 did not show differences compared to placebo on primary or secondary outcomes at week 24 in a mid-stage trial.

Amylyx Pharmaceuticals&nbsp;drew increased retail attention late Sunday after new clinical data presented at ENDO 2025 highlighted the potential of its lead candidate, avexitide, to significantly reduce dangerous blood sugar drops in patients with post-bariatric hypoglycemia (PBH).In a Phase 2b trial, avexitide 90 mg once daily, the dose being studied in the pivotal Phase 3 Lucidity trial, led to a 64% least-squares mean reduction in the composite rate of Level 2 and Level 3 hypoglycemic events.&nbsp;More than half of the participants experienced no severe events during the treatment period.Avexitide is a treatment being developed for post-bariatric hypoglycemia, a condition that currently has no approved therapies. Backed by FDA Breakthrough Therapy designation, the once-daily pill is designed to block the GLP-1 receptor and help prevent dangerous blood sugar drops.&nbsp;New data shared at ENDO 2025 showed that the 90 mg dose maintained steady, around-the-clock activity.&nbsp;A Phase 3 study called Lucidity is now underway, with plans to enroll about 75 people who’ve previously undergone gastric bypass surgery.&nbsp;Amylyx expects to finish signing up participants in 2025 and release the results in the first half of 2026.The data and trial momentum come amid fresh bullish coverage from Wall Street.&nbsp;Goldman Sachs resumed coverage on Amylyx with a ‘Buy’ rating and $10 price target, citing avexitide’s "blockbuster" potential.&nbsp;Guggenheim also started coverage last month with a ‘Buy’ and a $17 target, calling PBH a “not-so-rare” endocrine disease with 50,000–100,000 moderate-to-severe patients in the U.S.&nbsp;Citi joined with a ‘Buy’ and $12 target, highlighting multiple late-stage programs and "clear" clinical endpoints across four high-unmet-need indications.On Stocktwits, retail sentiment for Amylyx was ‘bullish’ amid ‘high’ message volume.Amylyx’s stock has risen 96.4% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crinetics-pharma-s-oral-drug-shows-lasting-relief-for-acromegaly-patients-in-latest-study-retail-buzz-builds/ch8B1oBR5Nq">Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Amylyx Pharmaceuticals (AMLX) highlighted the potential of its lead candidate avexitide to significantly reduce dangerous blood sugar drops in patients with post-bariatric hypoglycemia. (Photo credit: Getty Images)

Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial

The company is advancing the treatment into a Phase 3 study with results expected in 2026. 

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will participate in the following upcoming investor conferences, which are being conducted...

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025. Amylyx senior management team will...

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that Amylyx management will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference. The...

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial...

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.44	--	--	N/A
Q2 '25	-$0.44	-$0.46	-3.50%	MISSED
Q1 '25	-$0.47	-$0.42	11.58%	BEAT
Q4 '24	-$0.52	-$0.55	-5.77%	MISSED
Q3 '24	-$0.70	-$1.07	-51.99%	MISSED

AMLX
Amylyx Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest AMLX News

AMLXAmylyx Pharmaceuticals Inc